TY - JOUR JO - EuroIntervention TI - Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial AB - <p><strong>Background:</strong> In the TALENT study, the sirolimus-eluting ultrathin strut Supraflex stent was non-inferior to the XIENCE stent for a device-oriented composite endpoint (DoCE: defined as cardiac death, target-vessel myocardial infarction [TV-MI], or clinically indicated target lesion revascularisation [CI-TLR]) at 12 months.</p> <p><strong>Aims:</strong> This study investigated the 3-year outcomes of the TALENT trial and long-term impact of ultrathin drug-eluting stents (DES), compared to the XIENCE everolimus-eluting thin stent.</p> <p><strong>Methods:</strong> The TALENT trial is a prospective, multicentre, randomised all-comers trial comparing the Supraflex sirolimus-eluting stent with the XIENCE everolimus-eluting stent, with planned follow-up for 3 years.</p> <p><strong>Results:</strong> The TALENT trial enrolled 1,435 patients (Supraflex n=720, XIENCE n=715) with 3-year follow-up data available in 97.8% in the Supraflex group, and in 98.9% in the XIENCE group. At 3 years, DoCE occurred in 57 patients (8.1%) in the Supraflex group, and in 66 patients (9.4%) in the XIENCE group (p=0.406). There were no significant between-group differences in rates of cardiac death, TV-MI or CI-TLR. The rates of definite or probable stent thrombosis were low and similar between groups (1.1% vs 1.4%; p=0.640). In a meta-analysis of long-term follow-up (3-5 years), ultrathin strut DES tended to reduce DoCE (relative risk 0.89 [0.79-1.01]; p=0.068), compared to thicker strut DES. The risks for cardiac death and definite or probable stent thrombosis were similar between ultrathin strut DES and thicker strut DES.</p> <p><strong>Conclusions:</strong> At 3-year follow-up, the use of the Supraflex stent was at least as safe and efficacious as the XIENCE stent in an all-comers population. ClinicalTrials.gov: NCT02870140</p> AU - de Winter J. Robbert AU - Zaman Azfar AU - Hara Hironori AU - Gao Chao AU - Ono Masafumi AU - Garg Scot AU - Smits Pieter C. AU - Tonino A.L. Pim AU - Hofma H. Sjoerd AU - Moreno Raul AU - Choudhury Anirban AU - Petrov Ivo AU - Cequier Angel AU - Colombo Antonio AU - Kaul Upendra AU - Onuma Yoshinobu AU - Serruys Patrick W. VL - IS - Y1 - 15/03/2022 Y1 - 2022 DOI - 10.4244/EIJ-D-21-00766 SP - KW - clinical trials KW - drug-eluting stent KW - innovation PB - Europa Digital & Publishing UR - https://eurointervention.pcronline.com/article/sirolimus-eluting-stents-with-ultrathin-struts-versus-everolimus-eluting-stents-for-patients-undergoing-percutaneous-coronary-intervention-final-three-year-results-of-the-talent-trial SN - 1774-024X ER -